每晚一次的氧酸盐 (FT218) 在1型和2型麻醉症中的有效性:来自第三期REST-ON试验的后期分析
Yves Dauvilliers1, Thomas Roth2, Richard Bogan3,4
1Department of Neurology, Sleep-Wake Disorders Center, Gui-de-Chauliac Hospital, Institute for Neurosciences of Montpellier INM, INSERM, University of Montpellier, Montpellier, France.
Sleep
|May 29, 2023
概括
延长释放每晚一次的氧酸盐 (ON-SXB) 显著改善了1型和2型麻醉症患者的白天嗜睡和夜间睡眠障碍. 这种治疗为麻醉症患者提供了临床上有意义的选择.
科学领域:
- 神经学 神经学
- 睡眠医学 睡眠医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 麻醉症是一种慢性神经系统疾病,由于过度的嗜睡和睡眠中断,严重影响白天的功能.
- 目前的麻醉症治疗方法往往存在局限性,需要开发更有效的治疗方案.
研究的目的:
- 评估与安慰剂相比,每晚一次的延长释放氧化 (ON-SXB) 在治疗白天嗜睡和夜间睡眠中断方面的疗效.
- 单独评估ON-SXB在1型麻醉症 (NT1) 和2型麻醉症 (NT2) 患者中的有效性.
主要方法:
- 对第3阶段REST-ON试验数据的后期分析.
- 具有NT1 (n=145) 和NT2 (n=45) 的参与者 (N=190) 被随机分配到ON-SXB (定位至9g) 或安慰剂,每晚服用一次.
- 使用保持清醒测试 (MWT),临床全局印象改善 (CGI-I) 和患者报告的结果,包括睡眠质量和爱普沃思睡眠度量表 (ESS) 来评估有效性.
主要成果:
- 与安慰剂相比,ON-SXB对NT1和NT2亚组的睡眠延迟 (MWT) 显著改善.
- 在接受ON-SXB治疗的患者中,更大比例的患者在两种麻醉症类型中报告了显著的临床改善 (CGI-I).
- 通过ON-SXB在两个小组中观察到睡眠质量,睡眠阶段转换,夜间唤醒和ESS分数的显著改善.
结论:
- 单一的ON-SXB睡前剂量为NT1和NT2患者的白天嗜睡和夜间睡眠中断提供了临床上有意义的改善.
- ON-SXB是治疗麻醉症症状的有前途的治疗方案.
相关概念视频
Sleep-Wake Cycles
1.4K
Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
1.4K
Narcolepsy
158
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
158
Management of Insomnia
287
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
287
Sedatives and Hypnotics Drugs: Miscellaneous Agents
205
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
205
Substance Use Disorders Affecting Sleep
199
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Understanding the concepts of physical dependence,...
199
Antiepileptic Drugs: Potassium Channel Activators
221
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
221


